Clinical Trial Update: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2b trial of BMS-986094 and daclatasvir for chronic hepatitis C has been withdrawn, with or without ribavirin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-986094 (BMS-986094)
• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 2 | Status: WITHDRAWN